Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Capital Expenditures (2022 - 2024)

Zentalis Pharmaceuticals (ZNTL) has 3 years of Capital Expenditures data on record, last reported at $181000.0 in Q2 2024.

  • For Q2 2024, Capital Expenditures fell 43.26% year-over-year to $181000.0; the TTM value through Mar 2025 reached $181000.0, down 70.95%, while the annual FY2024 figure was $221000.0, 62.09% down from the prior year.
  • Capital Expenditures reached $181000.0 in Q2 2024 per ZNTL's latest filing, up from $40000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.7 million in Q3 2022 and bottomed at $40000.0 in Q1 2024.
  • Average Capital Expenditures over 3 years is $372444.4, with a median of $181000.0 recorded in 2024.
  • The widest YoY moves for Capital Expenditures: up 8.13% in 2023, down 94.52% in 2023.
  • A 3-year view of Capital Expenditures shows it stood at $160000.0 in 2022, then rose by 8.12% to $173000.0 in 2023, then rose by 4.62% to $181000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $181000.0 in Q2 2024, $40000.0 in Q1 2024, and $173000.0 in Q4 2023.